Who may be suitable?
Dynamic facial lines may be assessed after reviewing facial movement, brow and eyelid position, medical history, medicines and previous treatments. Some concerns need another approach or no procedure.
Botulinum toxin type A injections can temporarily soften dynamic expression lines in suitable adults. Assessment considers muscle activity, brow and eyelid position, medical history, the specific product and its authorized use in Turkey, batch traceability and follow-up. Treatment has potential risks and is not appropriate for everyone.
Duration
10-15 minutes
Body Location
Forehead, glabella, crow’s feet, masseter or selected facial muscles after assessment
Preparation
Do not stop prescribed medication on your own. Tell the physician about aspirin, anticoagulants, and any medicine or supplement that may affect bleeding; changes are made only with the prescribing clinician. Report active infection or illness before treatment.
Follow-up Care
Onset and duration vary by product and individual response. The physician plans the review and any repeat treatment according to examination findings and the product labeling; there is no automatic repeat schedule.
After assessing facial movement and muscle activity, the physician injects botulinum toxin into selected muscles using a fine needle. The product, total dose and follow-up plan are recorded.
Botulinum toxin and dermal filler are often discussed together, but they address different tissues and goals. Botulinum toxin can temporarily reduce activity in selected muscles; filler may add volume or structural support in an appropriate patient. This comparison explains general decision factors; an individual choice requires facial assessment, medical history, and examination.
| Criterion | Botox (Botulinum Toxin) | Dermal Filler (Hyaluronic Acid) |
|---|---|---|
| Primary Goal | Relaxes expression muscles to reduce dynamic wrinkles (forehead, glabellar lines, crow's feet). | Restores volume loss, fills static lines and contours (lips, cheeks, nasolabial folds). |
| Mechanism of Action | Blocks acetylcholine release to temporarily reduce muscle contraction. | Delivers hyaluronic acid to tissue; binds water between cells, adds volume and structural support. |
| Procedure Duration | 10–15 minutes | 30–45 minutes |
| Onset of Results | 3–7 days, full effect at 2 weeks | Immediately visible; settles over 1–2 weeks as swelling resolves |
| Longevity | 3–4 months | 9–18 months depending on product |
| Reversible? | Its effect fades over time; there is no standard method that immediately reverses treatment. | Some hyaluronic-acid fillers may be reduced with physician-directed hyaluronidase; the speed and extent of response vary. Suspected vascular occlusion requires urgent assessment. |
| Downtime | Return to routine is often quick; bruising, headache, or temporary asymmetry can occur. | Swelling and bruising can occur; duration varies by area, product, and individual response. |
| Findings That Guide the Choice | Lines driven by muscle movement, muscle strength, and the balance of adjacent structures. | Volume loss, contour needs, tissue quality, and vascular anatomy. |
| How Is the Fee Determined? | The muscles assessed, dose, product, and review plan are determined after physician examination. | Product type, amount, treatment area, technique, and follow-up plan are determined after physician examination. |
Dr. Gemici's Recommendation
Movement-related lines may prompt a botulinum-toxin assessment, while volume or structural-support needs may prompt a filler assessment. Some people may be considered for both approaches at different times, but age alone is not a decision rule. Suitability, expected benefit, and risks should be discussed during an in-person physician assessment.
Botulinum toxin decision guide
A responsible plan starts with the clinical goal, examination and the exact product. A brand name, a standard number of units or a recurring booking is not an individual treatment plan.
Dynamic facial lines may be assessed after reviewing facial movement, brow and eyelid position, medical history, medicines and previous treatments. Some concerns need another approach or no procedure.
Ask about the exact medicine, manufacturer, batch, expiry date, source, storage and authorized indication in Turkey. A US approval does not establish Turkish authorization. Units are product-specific and cannot be directly converted between brands.
Anatomy, muscle activity, prior response and the chosen product inform planning. A comparison study using equal numerical doses does not prove universal dose equivalence. This guide does not provide self-injection or dosing instructions.
No. Review assesses response and unwanted effects. Additional or repeat treatment depends on examination, the product information and the individual situation; it is not an automatic fixed schedule.
Difficulty breathing, swallowing or speaking, or generalized weakness after treatment needs urgent medical assessment. Do not wait for a routine follow-up. Bruising and local discomfort are different from these warning signs.
No, results typically appear after 3-7 days and full effect develops within 2 weeks.
The effect is temporary and varies by product, treated area and individual response. Duration is not a fixed repeat-treatment instruction; the physician reassesses suitability and follows the product labeling.
Minimal discomfort is experienced. Most patients do not need additional anesthesia, but topical anesthesia can be applied if requested.
Pregnant, nursing, or patients with neuromuscular disorders or botulinum toxin allergy should not receive it. Full evaluation during consultation.
Tenderness, bruising, headache or unintended muscle weakness may be temporary, but symptoms should not automatically be dismissed. New eyelid drooping requires medical review. Trouble breathing or swallowing, speech changes or generalized weakness require urgent medical attention.
This page does not provide a fixed price offer. Fees are confirmed after physician assessment based on product or device requirements, treatment area, session plan, and medical suitability.
Yes, can be combined with fillers, mesotherapy, or skin rejuvenation. Doctor plans for optimal results in same session.
Yes, immediately. Just avoid massaging face and intense exercise for first 24 hours.
Botox (Botulinum Toxin) Treatment is a safe procedure; still, as with any medical treatment, explaining possible side effects and rare complications transparently is part of patient safety. The physician-authored guides below cover these topics in depth.
This content is informational and does not replace medical advice. At any warning sign, contact the physician who performed the procedure or the nearest medical facility without delay.
Deep-dive in our glossary: definition, indications, side effects and FAQs.
Baby Botox is an intramuscular injection treatment that aims to prevent wrinkles in young patients between the ages of 20-35, with a dose reduced to 30-50% of the classical botox, and gives maximum priority to preserving natural facial expressions.
Axillary hyperhidrosis, primary focal hyperhidrosis coded with ICD-10 R61.0, which causes excessive sweat secretion throughout the day, regardless of stress, due to the hyperactive operation of the eccrine sweat glands in the armpit area due to sympathetic cholinergic innervation; HDSS ≥ 3 is a medical condition that significantly reduces the quality of life of patients and provides 75-90% sweat reduction with Botox gold standard treatment.
Dysport is a muscle-nerve blocking injection treatment containing the active ingredient Botulinum toxin type A (abobotulinumtoxin-A) produced by Ipsen, approved by FDA (2009) and TITCK, which reduces dynamic wrinkles by blocking facial expression muscles; It is known as a Botox alternative.
Daxxify; Botulinum toxin type A product, developed by Revance Therapeutics, containing a peptide stimulator (RTP-004) and approved by the FDA for cosmetic indication in 2022, used in the treatment of glabellar wrinkles; It is a longer-acting alternative to Botox, with an effect duration of up to 6 months.
Jeuveau is a prescription botulinum toxin injection authorized in the US for specified adult glabellar lines; its units are not interchangeable with those of other toxin products.
These are selected peer-reviewed medical publications. Findings are limited to the studied product, device and indication; authorization and administration route require separate verification. Publication titles are retained in their original language for reliable lookup.
A double-blind, placebo-controlled trial in 264 participants supports the studied botulinum toxin A product for glabellar lines. Results do not automatically apply to every brand, dose or facial area.
Evidence summary reviewed by Dr. Hamza Gemici · · Review log
Contact Dr. Hamza Gemici’s clinic for individualized assessment and candidacy planning.